The cystic fibrosis therapeutics development network (CF TDN): A paradigm of a clinical trials network for genetic and orphan diseases

Advanced Drug Delivery Reviews

Volumn 54, Issue 11, 2002, Pages 1505-1528

  Goss, C H ^a,b   Mayer Hamblett, N ^a,b   Kronmal, R A ^b   Ramsey, B W ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Clinical trials; Cystic fibrosis; Multicenter; Networks

Indexed keywords

DISEASES; GENETIC ENGINEERING; HEALTH CARE; PATIENT TREATMENT;

CLINICAL RESEARCHES;

DRUG PRODUCTS;

CLINICAL TRIAL; CYSTIC FIBROSIS; DEVELOPMENT; GENETIC DISORDER; HUMAN; INTERNET; INTERPERSONAL COMMUNICATION; MEDICINE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RESEARCH; REVIEW; STATISTICAL ANALYSIS;

EID: 0037027942     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00163-1     Document Type: Article

References (74)

1. Friedman L.M., Furberg C.D., DeMets D.L. Fundamentals of Clinical Trials. 3rd Edition: 1996;Mosby-Year Book. pp. 1-13.
2. Bull J.P. The historical development of clinical therapeutic trials. J. Chronic Dis. 10:1959;218-248.
3. Lilienfeld A.M., The Fielding H. Garrison Lecture: Ceteris paribus: the evolution of the clinical trial. Bull. Hist Med. 56:1982;1-18.
4. Gluud C. Trials and errors in clinical research. Lancet. 354 (Suppl.):1999;SIV59.
5. Meinert C.L., Tonascia S. Clinical Trials: Design, Conduct, and Analysis. 1986;Oxford University Press, Oxford.
6. Box J.F. R.A. Fisher and the design of experiments, 1922-1926. Am. Stat. 34:1980;1-7.
7. Amberson J.B., McMahon B.T., Pinner M. A clinical trial of Sanocrysin in pulmonary tuberculosis. Am. Rev. Tuberc. 24:1931;401-435.
8. Diehl H.S., Baker A.B., Cowan D.W. Cold vaccines; an evaluation based on a controlled study. J. Am. Med. Assoc. 111:1938;1168-1173.
9. Intermittent positive pressure breathing therapy of chronic obstructive pulmonary disease. A clinical trial, Ann. Intern. Med. 99 (1983) 612-620.
10. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno D., Barker A.H., Arensberg D., Baker A., Friedman L., Greene H.L., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. 324:1991;781-788.
11. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. 321:1989;406-412.
12. Lamas G.A., Pfeffer M.A., Hamm P., Wertheimer J., Rouleau J.L., Braunwald E. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N. Engl. J. Med. 327:1992;241-247.
13. Friedman L., Wenger N.K., Knatterud G.L. Impact of the Coronary Drug Project findings on clinical practice. Control Clin. Trials. 4:1983;513-522.
14. Organization, review, and administration of cooperative studies (Greenberg Report): A report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967, Control Clin. Trials 9 (1988) 137-148.
15. Zukel W.J. Evolution and funding of the Coronary Drug Project. Control Clin. Trials. 4:1983;281-312.
16. Meinert C.L., Heinz E.C., Forman S.A. The Coronary Drug Project. Role and methods of the Coordinating Center. Control Clin. Trials. 4:1983;355-375.
17. The coronary drug project. Design, methods, and baseline results. Circulation 47 (1973) 11-150.
18. Canner P.L., Stamler J. The Coronary Drug Project. Organizational structure of the study. Control Clin. Trials. 4:1983;333-343.
19. Halperin M., DeMets D.L., Ware J.H. Early methodological developments for clinical trials at the National Heart, Lung and Blood Institute. Stat. Med. 9:1990;881-892.
20. Practical aspects of decision making in clinical trials: the coronary drug project as a case study. Control Clin. Trials. 1:1981;363-376.
21. Goetz F.C. Management of adult-onset diabetes. The impact of the University Group Diabetes Program. Postgrad. Med. 52:1972;63-68.
22. Carbone P.P. Organization of clinical oncology in the USA: role of cancer centers, cooperative groups and community hospitals. Eur. J. Cancer Clin. Oncol. 21:1985;149-154.
23. Carbone P.P., Tormey D.C. Organizing multicenter trials: lessons from the cooperative oncology groups. Prev. Med. 20:1991;162-169.
24. Begg C.B., Carbone P.P., Elson P.J., Zelen M. Participation of community hospitals in clinical trials: analysis of 5 years of experience in the Eastern Cooperative Oncology Group. N. Engl. J. Med. 306:1982;1076-1080.
25. Hillman B.J., Gatsonis C., Sullivan D.C. American College of Radiology Imaging Network: new national cooperative group for conducting clinical trials of medical imaging technologies. Radiology. 213:1999;641-645.
26. Kephart D.K., Chinchilli V.M., Hurd S.S., Cherniack R.M. The organization of the Asthma Clinical Research Network: a multicenter, multiprotocol clinical trials team. Control Clin. Trials. 22:2001;119S-125S.
27. Chinchilli V.M., Drazen J.M., Fish J.E., Lemanske R.F. Jr., Lazarus S.C., Martin R.J. The clinical trials in the initial 5-year award period of the Asthma Clinical Research Network. Control Clin. Trials. 22:2001;126S-134S.
28. Chinchilli V.M. The Asthma Clinical Research Network. Control Clin. Trials. 22:2001;117S-118S.
29. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N. Engl. J. Med. 342:2000;1301-1308.
30. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. J. Am. Med. Assoc. 283:2000;1995-2002.
31. Kraemer H.C., Pruyn J.P. The evaluation of different approaches to randomized clinical trials. Report on the 1987 MacArthur Foundation Network I Methodology Workshop. Arch. Gen. Psychiatry. 47:1990;1163-1169.
32. Cheng K., Smyth R.L., Motley J., O'Hea U., Ashby D. Randomized controlled trials in cystic fibrosis (1966-1997) categorized by time, design, and intervention. Pediatr. Pulmonol. 29:2000;1-7.
33. Pattishall E.N. Negative clinical trials in cystic fibrosis research. Pediatrics. 85:1990;277-281.
34. Robinson P. Cystic fibrosis. Thorax. 56:2001;237-241.
35. Cystic Fibrosis Foundation, Patient Registry 1999 Annual Data Report, Bethesda, MA, 2000, pp. 1-2.
36. Rosenstein B.J., Cutting G.R. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel [see comments]. J. Pediatr. 132:1998;589-595.
37. Knowles M., Gatzy J., Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N. Engl. J. Med. 305:1981;1489-1495.
38. Knowles M.R., Paradiso A.M., Boucher R.C. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum. Gene Ther. 6:1995;445-455.
39. Khan T.Z., Wagener J.S., Bost T., Martinez J., Accurso F.J., Riches D.W. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 151:1995;1075-1082.
40. Armstrong D.S., Grimwood K., Carlin J.B., Carzino R., Olinsky A., Phelan P.D. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr. Pulmonol. 21:1996;267-275.
41. Ramsey B.W. What is the role of upper airway bacterial cultures in patients with cystic fibrosis? Pediatr. Pulmonol. 21:1996;265-266.
42. Rosenfeld M., Gibson R.L., McNamara S., Emerson J., Burns J.L., Castile R., Hiatt P., McCoy K., Wilson C.B., Inglis A., Smith A., Martin T.R., Ramsey B.W. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr. Pulmonol. 32:2001;356-366.
43. Turner D.J., Stick S.M., Lesouef K.L., Sly P.D., Lesouef P.N. A new technique to generate and assess forced expiration from raised lung volume in infants. Am. J. Respir. Crit. Care Med. 151:1995;1441-1450.
44. Jones M., Castile R., Davis S., Kisling J., Filbrun D., Flucke R., Goldstein A., Emsley C., Ambrosius W., Tepper R.S. Forced expiratory flows and volumes in infants. Normative data and lung growth. Am. J. Respir. Crit. Care Med. 161:2000;353-359.
45. Castile R., Filbrun D., Flucke R., Franklin W., McCoy K. Adult-type pulmonary function tests in infants without respiratory disease. Pediatr. Pulmonol. 30:2000;215-227.
46. Noone P.G., Hamblett N., Accurso F., Aitken M.L., Boyle M., Dovey M., Gibson R., Johnson C., Kellerman D., Konstan M.W., Milgram L., Mundahl J., Retsch-Bogort G., Rodman D., Williams-Warren J., Wilmott R.W., Zeitlin P., Ramsey B. Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr. Pulmonol. 32:2001;122-128.
47. Rosenfeld M., Gibson R., McNamara S., Emerson J., McCoyd K.S., Shell R., Borowitz D., Konstan M.W., Retsch-Bogart G., Wilmott R.W., Burns J.L., Vicini P., Montgomery A.B., Ramsey B. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J. Pediatr. 139:2001;572-577.
48. Aitken M.L., Moss R.B., Waltz D.A., Dovey M.E., Tonelli M.R., McNamara S.C., Gibson R.L., Ramsey B.W., Carter B.J., Reynolds T.C. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum. Gene Ther. 12:2001;1907-1916.
49. Neaton J.D., Bartsch G.E., Broste S.K., Cohen J.D., Simon N.M. A case of data alteration in the Multiple Risk Factor Intervention Trial (MRFIT). Control Clin. Trials. 12:1991;731-740.
50. Cohen J. Clinical trial monitoring: hit or miss? Science. 264:1994;1534-1537.
51. R. Weiss, D. Nelson, Methods Faulted in Fatal Gene Therapy, The Washington Post, 12/8/1999, A1.
52. S.G. Stolberg, Institute Restricted After Gene Therapy Death, The New York Times, 5/25/2000.
53. Greenberg D.S. Slow progress towards protecting people in US clinical trials. Lancet. 355:2000;1527.
54. Greenberg D.S. Stricter regulation proposed for US gene-therapy trials. Lancet. 355:2000;1977.
55. Shalala D. Protecting research subjects - what must be done. N. Engl. J Med. 343:2000;808-810.
56. Kumar S. US university finds scientist flouted rules for clinical trials. Lancet. 358:2001;1791.
57. S. Levine, Hopkins Researcher Faulted in Death, The Washington Post, 7/17/2001, B07.
58. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J Med. 345:2001;851-860.
59. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345:2001;861-869.
60. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345:2001;870-878.
61. Kurtzman N.A. Drug companies should not have the final say in the design of clinical trials. Am. J. Kidney Dis. 38:2001;1113-1114.
62. Henderson L. More AMCs finding growth from reform. CenterWatch. 1:2000;10-13.
63. Davidoff F., DeAngelis C.D., Drazen J.M., Nicholls M.G., Hoey J., Hojgaard L., Horton R., Kotzin S., Nylenna M., Overbeke A.J., Sox H.C., Van Der Weyden M.B., Wilkes M.S. Sponsorship, authorship, and accountability. N. Engl. J. Med. 345:2001;825-826.
64. W. Duff, D. Heath, Uninformed Consent, Seattle Times, 3/13/2001.
65. W. Duff, D. Heath, Hutch should prohibit financial conflicts of interest, panel recommends, Seattle Times, 9/7/2001.
66. DerSimonian R., Charette L.J., McPeek B., Mosteller F. Reporting on methods in clinical trials. N. Engl. J. Med. 306:1982;1332-1337.
67. Huston P., Moher D. Redundancy, disaggregation, and the integrity of medical research. Lancet. 347:1996;1024-1026.
68. Johansen H.K., Gotzsche P.C. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. J. Am. Med. Assoc. 282:1999;1752-1759.
69. Rennie D. Fair conduct and fair reporting of clinical trials. J. Am. Med. Assoc. 282:1999;1766-1768.
70. Kaushansky K. Removing the cloud from industry-sponsored, multicentered clinical trials. Blood. 98:2001;2001.
71. Hawkey C.J. Journals should see original protocols for clinical trials. Br. Med. J. 323:2001;1309.
72. Begg C., Cho M., Eastwood S., Horton R., Moher D., Olkin I., Pitkin R., Rennie D., Schulz K.F., Simel D., Stroup D.F. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. J. Am. Med. Assoc. 276:1996;637-639.
73. Moher D., Schulz K.F., Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. J. Am. Med. Assoc. 285:2001;1987-1991.
74. Schuster D., Canfield D. MACRO: A new paradigm for clinical research among academic health centers. Clin. Res. 6:2001;34-36.